TrialBlood advances2023

A phase 2 trial of defibrotide for the prevention of chimeric antigen receptor T-cell-associated neurotoxicity syndrome.

Caron A Jacobson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.